The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy

Ornella Sortino; Katherine Huppler Hullsiek; Elizabeth Richards; Adam Rupert; Andrea Schminke; Namo Tetekpor; Mariam Quinones; Rachel Prosser; Tim Schacker; Irini Sereti; Jason V. Baker

doi:10.1093/infdis/jiz042

The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy

Ornella Sortino, Katherine Huppler Hullsiek, Elizabeth Richards, Adam Rupert, Andrea Schminke, Namo Tetekpor, Mariam Quinones, Rachel Prosser, Tim Schacker, Irini Sereti, Jason V. Baker

Biostatistics

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/μ L. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation.

Original language	English (US)
Pages (from-to)	1963-1968
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	219
Issue number	12
DOIs	https://doi.org/10.1093/infdis/jiz042
State	Published - Jun 1 2019

Bibliographical note

Funding Information:
Financial support. This work was supported by Hennepin Health Services (career development award), the intramural research program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), the National Cancer Institute, NIH (contract HHSN261200800001E), the intramural research program of NIAID/NIH and the NIAID microbiome core facility, and Ventria Bioscience (provision of study drug, including both active rh-lactoferrin tablets and matching placebo).

Publisher Copyright:
© 2019 The Author(s).

Keywords

HIV
Immune activation
Inflammation
Lactoferrin
Microbiome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1093/infdis/jiz042

OpenUrl availability

Full text

Cite this

Sortino, O., Huppler Hullsiek, K., Richards, E., Rupert, A., Schminke, A., Tetekpor, N., Quinones, M., Prosser, R., Schacker, T., Sereti, I., & Baker, J. V. (2019). The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy. Journal of Infectious Diseases, 219(12), 1963-1968. https://doi.org/10.1093/infdis/jiz042

The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy. / Sortino, Ornella; Huppler Hullsiek, Katherine; Richards, Elizabeth et al.
In: Journal of Infectious Diseases, Vol. 219, No. 12, 01.06.2019, p. 1963-1968.

Research output: Contribution to journal › Article › peer-review

Sortino, O, Huppler Hullsiek, K, Richards, E, Rupert, A, Schminke, A, Tetekpor, N, Quinones, M, Prosser, R, Schacker, T, Sereti, I & Baker, JV 2019, 'The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy', Journal of Infectious Diseases, vol. 219, no. 12, pp. 1963-1968. https://doi.org/10.1093/infdis/jiz042

@article{13a8ac850ee44e68b266ff7639805681,

title = "The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy",

abstract = "Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/μ L. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation.",

keywords = "HIV, Immune activation, Inflammation, Lactoferrin, Microbiome",

author = "Ornella Sortino and {Huppler Hullsiek}, Katherine and Elizabeth Richards and Adam Rupert and Andrea Schminke and Namo Tetekpor and Mariam Quinones and Rachel Prosser and Tim Schacker and Irini Sereti and Baker, {Jason V.}",

note = "Funding Information: Financial support. This work was supported by Hennepin Health Services (career development award), the intramural research program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), the National Cancer Institute, NIH (contract HHSN261200800001E), the intramural research program of NIAID/NIH and the NIAID microbiome core facility, and Ventria Bioscience (provision of study drug, including both active rh-lactoferrin tablets and matching placebo). Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = jun,

day = "1",

doi = "10.1093/infdis/jiz042",

language = "English (US)",

volume = "219",

pages = "1963--1968",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy

AU - Sortino, Ornella

AU - Huppler Hullsiek, Katherine

AU - Richards, Elizabeth

AU - Rupert, Adam

AU - Schminke, Andrea

AU - Tetekpor, Namo

AU - Quinones, Mariam

AU - Prosser, Rachel

AU - Schacker, Tim

AU - Sereti, Irini

AU - Baker, Jason V.

N1 - Funding Information: Financial support. This work was supported by Hennepin Health Services (career development award), the intramural research program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), the National Cancer Institute, NIH (contract HHSN261200800001E), the intramural research program of NIAID/NIH and the NIAID microbiome core facility, and Ventria Bioscience (provision of study drug, including both active rh-lactoferrin tablets and matching placebo). Publisher Copyright: © 2019 The Author(s).

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/μ L. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation.

AB - Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4+ cell count was 651/μ L. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation.

KW - HIV

KW - Immune activation

KW - Inflammation

KW - Lactoferrin

KW - Microbiome

UR - http://www.scopus.com/inward/record.url?scp=85066949855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066949855&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz042

DO - 10.1093/infdis/jiz042

M3 - Article

C2 - 30721997

AN - SCOPUS:85066949855

SN - 0022-1899

VL - 219

SP - 1963

EP - 1968

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 12

ER -

The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this